• Home
  • Market Opportunity
  • Technology
  • Patents
  • Leadership
  • Contact
  • More
    • Home
    • Market Opportunity
    • Technology
    • Patents
    • Leadership
    • Contact
  • Home
  • Market Opportunity
  • Technology
  • Patents
  • Leadership
  • Contact
Epipace

RETHINKING CARDIAC PACING

RETHINKING CARDIAC PACINGRETHINKING CARDIAC PACING

A Global Intellectual Property Portfolio

EPIPACE is supported by a core patent family covering systems, methods, and devices for treating bradyarrhythmias, tachyarrhythmias, and heart failure. The portfolio includes issued, allowed, published, and pending rights across major international markets.

Revolutionizing Biotechnology

Issued and Granted Rights

Issued and Granted Rights

Issued and Granted Rights

  • United States — US 11,103,710 B2
  • European Patent — EP 3,801,232 B1
  • Japan — JP 7,456,596 B2
  • Israel — IL 279046
  • Hong Kong — HK 40049682 B

Pending applications

Issued and Granted Rights

Issued and Granted Rights

  • Canada — CA 3,102,104
  • China — CN 112399825 A
  • United States — new continuation application filed in 2026

Patent status reflects information as of July 2026. The portfolio includes granted patents in the USA, Europe, Japan, Israel, and Hong Kong; pending applications in Canada and China; a newly filed U.S. continuation application; and a pending request to revive the Brazilian application. Status may change as prosecution, reinstatement proceedings, and maintenance continue

Copyright © 2026 Epipace - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept